S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up

AVITA Medical Stock Price, News & Analysis (NASDAQ:RCEL)

$10.85
+0.12 (+1.12%)
(As of 11/27/2023 ET)
Compare
Today's Range
$10.46
$10.98
50-Day Range
$9.29
$14.87
52-Week Range
$6.29
$21.70
Volume
124,795 shs
Average Volume
193,875 shs
Market Capitalization
$277.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.40

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.3% Upside
$26.40 Price Target
Short Interest
Healthy
2.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of AVITA Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$25,030 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.47) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

241st out of 936 stocks

Surgical & Medical Instruments Industry

29th out of 92 stocks


RCEL stock logo

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

RCEL Stock News Headlines

Important info on NVDA trade
Today, I’m pulling back the curtain on my all-new Everyday Income project. A way for everyday folks to target a couple hundred bucks or more every single day the markets are open… Without breaking a sweat!
AVITA Medical: Q3 Earnings Insights
Important info on NVDA trade
Today, I’m pulling back the curtain on my all-new Everyday Income project. A way for everyday folks to target a couple hundred bucks or more every single day the markets are open… Without breaking a sweat!
Avita Medical (ASX: AVH)
5 Best Cosmetic Surgery and Aesthetics Stocks to Buy
Expert Ratings for AVITA Medical
Avita Medical (RCEL) Earnings Dates & Reports
AVITA Medical Reports Second Quarter Financial Results
See More Headlines
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
11/27/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCEL
Fax
N/A
Employees
126
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$26.40
High Stock Price Target
$40.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+143.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-26,670,000.00
Pretax Margin
-73.98%

Debt

Sales & Book Value

Annual Sales
$34.42 million
Book Value
$3.39 per share

Miscellaneous

Free Float
25,027,000
Market Cap
$277.22 million
Optionable
Not Optionable
Beta
1.54

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. James M. Corbett (Age 65)
    CEO, President & Executive Director
    Comp: $787.1k
  • Mr. Andrew Quick (Age 52)
    Chief Technology Officer
    Comp: $615.86k
  • Ms. Donna Shiroma (Age 61)
    General Counsel & Secretary
    Comp: $642.72k
  • Mr. David O'Toole
    Chief Financial Officer
  • Mr. David Fencil
    Senior Vice President of Global Operations
  • Ms. Jessica Ekeberg
    Investor Relations Executive
  • Ms. Debbie Garner
    Senior Vice President of Global Marketing & Strategy
  • Mr. Rob Hall
    Senior Vice President of Human Resources
  • Mr. Terry Bromley
    Senior Vice President of Global Sales
  • Dr. Niraj Doshi J.D.
    P.M.P., Ph.D., Senior Vice President of Product Development & Program Management














RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCEL shares.
View RCEL analyst ratings
or view top-rated stocks.

What is AVITA Medical's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for AVITA Medical's stock. Their RCEL share price targets range from $19.00 to $40.00. On average, they predict the company's stock price to reach $26.40 in the next year. This suggests a possible upside of 143.3% from the stock's current price.
View analysts price targets for RCEL
or view top-rated stocks among Wall Street analysts.

How have RCEL shares performed in 2023?

AVITA Medical's stock was trading at $6.60 at the beginning of the year. Since then, RCEL shares have increased by 64.4% and is now trading at $10.85.
View the best growth stocks for 2023 here
.

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our RCEL earnings forecast
.

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) announced its earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.16. The firm had revenue of $7.02 million for the quarter, compared to the consensus estimate of $6.98 million. AVITA Medical had a negative trailing twelve-month return on equity of 45.82% and a negative net margin of 74.16%. During the same quarter in the previous year, the firm earned ($0.48) earnings per share.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical issued an update on its FY 2023 earnings guidance on Wednesday, October, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51.00 million-$53.00 million, compared to the consensus revenue estimate of $52.41 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).

Who are AVITA Medical's major shareholders?

AVITA Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include EAM Investors LLC (0.98%), Bank of New York Mellon Corp (0.50%), Charles Schwab Investment Management Inc. (0.27%), Assenagon Asset Management S.A. (0.26%), Walleye Capital LLC (0.20%) and Invesco Ltd. (0.13%). Insiders that own company stock include David D O'toole, Donna Shiroma, Michael S Perry, Michael S Perry and Suzanne Crowe.
View institutional ownership trends
.

How do I buy shares of AVITA Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -